´ë»ç °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½Ì °è¾à(2019-2025³â)
Metabolic Collaboration and Licensing Deals 2019-2025
»óǰÄÚµå : 1708058
¸®¼­Ä¡»ç : Current Partnering, a brand of Biopharma Research Ltd.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 300+ Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,995 £Ü 5,780,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,995 £Ü 8,674,000
PDF (Multi User License - 2 to 5 Users) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 2-5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,995 £Ü 11,567,000
PDF (Company Wide License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´ë»ç °øµ¿¿¬±¸ ¹× ¶óÀ̼±½Ì °è¾àÀº ¼¼°è ÁÖ¿ä ¹ÙÀÌ¿À±â¾÷ÀÌ Ã¼°áÇÑ ´ë»ç °è¾à¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀÌÇØ¿Í ÇÔ²² Àü·Ê ¾ø´Â Á¢±Ù¼ºÀ» Á¦°øÇÕ´Ï´Ù.

2019-2025³â 576°ÇÀÇ ´ë»ç °Å·¡¿¡ ´ëÇÑ ¼¼ºÎ Á¤º¸¸¦ Á¦°øÇϵµ·Ï Àü¸é ¼öÁ¤ ¹× ¾÷µ¥ÀÌÆ®µÇ¾ú½À´Ï´Ù.

´ç»çÀÚ °£¿¡ ¹ßÇ¥µÈ °Å·¡ÀÇ ÁöºÒ Á¶°Ç¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â ÁöºÒ Á¶°Ç ¹× ±âŸ °Å·¡ Á¶°Ç¿¡ ´ëÇÑ À¯¿ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

ÆÄÆ®³Ê Èĺ¸ÀÇ Çù»óµÈ °Å·¡ Á¶°ÇÀÇ À¯¿¬¼ºÀ» ÀÌÇØÇϸé Çù»ó °úÁ¤¿¡¼­ ¹«¾ùÀ» ±â´ëÇÒ ¼ö ÀÖ´ÂÁö¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¸¹Àº Áß¼Ò±â¾÷ÀÌ ÁöºÒ Á¶°Ç¿¡ ´ëÇÑ ¼¼ºÎ »çÇ×À» ¿ä±¸ÇÒ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, ÁöºÒÀÌ ¾î¶»°Ô ¹ß»ýÇÏ°í ±Ç¸®°¡ ¾î¶»°Ô ÀÌÀüµÇ´ÂÁö, ¾Ç¸¶´Â µðÅ×ÀÏ¿¡ ¼û¾îÀÖ´Ù°í ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Current AgreementsÀÇ °Å·¡ ¹× Á¦ÈÞ µ¥ÀÌÅͺ£À̽º¿¡ ±â·ÏµÈ 2019³â ÀÌÈÄ ¹ßÇ¥µÈ Á¦ÈÞ ¹× ¶óÀ̼±½º °è¾àÀÇ Á¾ÇÕÀûÀÎ ¸®½ºÆ®°ú À繫 Á¶°ÇÀÌ Æ÷ÇÔµÈ °æ¿ì, ±â¾÷°ú ÆÄÆ®³Ê°¡ Áõ±Ç°Å·¡À§¿øÈ¸¿¡ Á¦ÃâÇÑ ½ÇÁ¦ ¶óÀ̼±½º °è¾à¼­ »çº»ÀÇ ¿Â¶óÀÎ »çº» ¸µÅ©°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ÇÑ ½ÇÁ¦ ¶óÀ̼±½º °è¾à ¹®¼­ÀÇ ¿Â¶óÀÎ »çº»¿¡ ´ëÇÑ ¸µÅ©µµ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ Ã¹ ¹øÂ° Àå¿¡¼­´Â ¸ÞŸº¼¸¯ °Å·¡¿Í »ç¾÷ Ȱµ¿ÀÇ ¹æÇ⼺À» Á¦½ÃÇÕ´Ï´Ù. 1Àå¿¡¼­´Â ÀÌ º¸°í¼­ÀÇ ¼Ò°³¸¦, 2Àå¿¡¼­´Â ¸ÞŸº¼¸¯ÀÇ °Å·¡ ¸ÞÀÌÅ· µ¿ÇâÀ» ºÐ¼®ÇÕ´Ï´Ù.

3Àå¿¡¼­´Â ´ë»ç ºÐ¾ß¿¡¼­ ü°áµÈ °Å·¡ÀÇ À繫Àû °Å·¡ Á¶°ÇÀ» °³¹ß ´Ü°è¿Í ÇÔ²² ¹ßÇ¥ÇÕ´Ï´Ù. °Å·¡´Â ¸®½ºÆ®È­µÇ¾î ÀÖÀ¸¸ç, °è¾à±Ý, °è¾à ÀϽñÝ, ¸¶ÀϽºÅæ Áö±Þ, ·Î¿­Æ¼ ºñÀ²º°·Î ±¸ºÐµÇ¾î ÀÖ½À´Ï´Ù.

4Àå¿¡¼­´Â ´ë»ç ºÐ¾ß¿¡¼­ °¡Àå Ȱ¹ßÇÏ°Ô °Å·¡¸¦ ¼º»ç½Ã۰í ÀÖ´Â »óÀ§ 25°³ ¹ÙÀÌ¿ÀÁ¦¾à±â¾÷¿¡ ´ëÇÑ ¸®ºä¿Í ÇÔ²² SEC¿¡ °ø½ÃµÈ °è¾à¼­°¡ ÀÖ´Â °Ç¿¡ ´ëÇØ´Â Current AgreementsÀÇ °Å·¡ ¹× Á¦ÈÞ µ¥ÀÌÅͺ£À̽º¸¦ ÅëÇØ ¿Â¶óÀÎÀ¸·Î °è¾à¼­¸¦ ¿­¶÷ÇÒ ¼ö ÀÖ´Â ¸µÅ©¸¦ Á¦°øÇÕ´Ï´Ù.¿¡¼­ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.

5Àå¿¡¼­´Â °è¾à ¹®¼­°¡ ÀÔ¼ö °¡´ÉÇÑ 2019³â ÀÌÈÄ Ã¼°á ¹× ¹ßÇ¥µÈ ´ë»ç °è¾àµéÀ» Á¾ÇÕÀûÀÌ°í »ó¼¼ÇÏ°Ô °ËÅäÇϰí ÀÖ½À´Ï´Ù. °¢ °è¾àÀÇ Á¦¸ñÀº À¥ ¸µÅ©¸¦ ÅëÇØ ½ÇÁ¦ °è¾à ¹®¼­ÀÇ ¿Â¶óÀÎ ¹öÀü·Î ¿¬°áµÇ¾î ÀÖÀ¸¸ç, Çʿ信 µû¶ó °¢ °è¾à ¹®¼­¿¡ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù.

6Àå¿¡¼­´Â Ä¡·á Ç¥Àûº°·Î ³ª¿­µÈ ´ë»ç ¾È°ÇµéÀ» Á¾ÇÕÀûÀ¸·Î Á¤¸®ÇÑ µð·ºÅ丮¸¦ Á¦°øÇÕ´Ï´Ù.

¶ÇÇÑ 2019³â ÀÌÈÄ ´ë»ç ¾È°ÇµéÀÇ µ¿Çâ°ú Ȱµ¿À» º¸¿©ÁÖ´Â µµÇ¥µµ ´Ù¼ö ¼ö·ÏµÇ¾î ÀÖ½À´Ï´Ù.

¶ÇÇÑ Á¾ÇÕÀûÀÎ °Å·¡ µð·ºÅ丮¸¦ ±â¾÷ A-Z ¹× ±â¼ú À¯Çüº°·Î Á¤¸®ÇÏ¿© Á¦°øÇÕ´Ï´Ù. °¢ °Å·¡ Á¦¸ñÀº À¥ ¸µÅ©¸¦ ÅëÇØ ¿Â¶óÀÎ ¹öÀüÀÇ °Å·¡ ±â·Ï·Î ¿¬°áµÇ¸ç, »ç¿ë °¡´ÉÇÑ °æ¿ì °è¾à ¹®¼­µµ °Ô½ÃµÇ¾î ÀÖÀ¸¸ç, °¢ °è¾à ¹®¼­¿¡ ´ëÇÑ ¿Âµð¸Çµå Á¢±ÙÀÌ ¿ëÀÌÇÕ´Ï´Ù.

ÁÖ¿ä ÀåÁ¡

´ë»ç °øµ¿ ¿¬±¸ ¹× ¶óÀ̼±½º °è¾àÀº µ¶Àڵ鿡°Ô ´ÙÀ½°ú °°Àº ÁÖ¿ä ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. :

Á¶»ç ¹üÀ§

º¸°í¼­ ³»¿ë

¸ñÂ÷

°³¿ä

Á¦1Àå ¼­·Ð

Á¦2Àå ´ë»ç °Å·¡ÀÇ µ¿Çâ

Á¦3Àå ´ë»ç Á¦ÈÞ ±ÝÀ¶°Å·¡ Á¶°Ç

Á¦4Àå ÁÖ¿ä ´ë»ç °Å·¡¿Í °Å·¡ ´ã´çÀÚ

Á¦5Àå ´ë»ç °è¾à ¹®¼­ µð·ºÅ丮

Á¦6Àå Ä¡·á Ç¥Àûº° ´ë»ç °Å·¡

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Metabolic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the metabolic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 576 metabolic deals from 2019 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in metabolic dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the metabolic field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in metabolic dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of metabolic deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of metabolic deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in metabolic deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Metabolic Collaboration and Licensing Deals provides the reader with the following key benefits:

Report scope

Metabolic Collaboration and Licensing Deals includes:

In Metabolic Collaboration and Licensing Deals, the available deals are listed by:

Analyzing contract agreements allows due diligence of:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

Chapter 3 - Financial deal terms for metabolic partnering

Chapter 4 - Leading metabolic deals and dealmakers

Chapter 5 - Metabolic contract document directory

Chapter 6 - Metabolic dealmaking by therapeutic target

Table of figures

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â